MET Stock Climbs as MetLife Announces $3 Billion Buyback Amid Q2 Earnings Beat

• California State Teachers Retirement System (CalSTRS) expanded its MetLife position by over 8,000% to hold 73.8 million shares valued at $6.24 billion in Q2 2026.
• BlackRock Inc. initiated a new position worth approximately $4.38 billion, signaling strong institutional confidence in the insurer .
• MetLife reported Q2 2026 earnings per share (EPS) of $2.43, exceeding the consensus estimate of $2.30 .
• The company authorized a new $3 billion share repurchase program, representing up to 4.8% of its outstanding shares .
• Wall Street consensus remains bullish with an average price target of $102.21 and multiple analyst upgrades in recent weeks.

MetLife Inc. (NYSE: MET) has solidified its position as a preferred holding among major institutional investors following a strong second quarter of 2026. The insurance giant reported earnings that surpassed market expectations, reinforcing the bullish sentiment surrounding its financial stability and capital allocation strategy. This performance was accompanied by significant buying activity from prominent pension funds and asset managers, who viewed the stock as undervalued relative to its intrinsic metrics.

The most notable development in institutional activity was the aggressive expansion of the California State Teachers Retirement System (CalSTRS). In the second quarter, CalSTRS increased its stake by 8,029%, purchasing 72.9 million additional shares. This move brought its total ownership to 11.47%, with the position valued at approximately $6.24 billion as of the reporting date . Such a dramatic increase in shareholding underscores the long-term confidence institutional players have in MetLife’s ability to generate consistent returns.

BlackRock Inc. also contributed to the wave of institutional buying by initiating a new position valued at roughly $4.38 billion . Other significant movements included Munich Reinsurance Co. starting a $7.34 million position and the Saudi Central Bank raising its stake by 87.7% . Collectively, institutional investors now hold 94.99% of MetLife’s outstanding stock, indicating a high level of professional conviction in the company’s trajectory . This widespread institutional support provides a stable floor for the stock, reducing volatility and signaling confidence in the management’s strategic direction.

Financially, MetLife delivered a mixed but ultimately positive quarter. The company reported an EPS of $2.43, beating the consensus estimate of $2.30 . However, revenue of $13.52 billion fell short of the $19.67 billion analyst expectation . Despite the revenue miss, the company demonstrated strong profitability, posting a net margin of 4.57% and a return on equity (ROE) of 23.39% . Year-over-year revenue growth stood at a solid 10.5%, reflecting the resilience of its core insurance and financial services operations .

To further reward shareholders and signal confidence in its valuation, MetLife’s Board of Directors authorized a new $3 billion share repurchase program. This new authorization is incremental to the approximately $600 million remaining from a prior program as of April 2024. The buyback allows the company to repurchase up to 4.8% of its outstanding shares, a move typically interpreted as management believing the stock is undervalued . Concurrently, MetLife declared a quarterly dividend of $0.5925 per share, yielding approximately 2.5% annually with a sustainable payout ratio of 45.40% .

Wall Street analysts have responded positively to these developments, with several major firms raising their price targets and ratings. Morgan Stanley upgraded its target to $111.00 with an Overweight rating, while KBW raised its target to $108.00 with an Outperform rating . TD Cowen increased its target to $105.00 and Jefferies to $103.00, both maintaining Buy ratings . The average consensus price target currently stands at $102.21, suggesting upside potential from the stock’s recent trading levels near $97.66 .

How Do Institutional Buying Trends Affect MET Valuation?

The massive influx of institutional capital into MetLife has had a direct impact on its market valuation. With 94.99% of the stock held by institutions, the share supply available for public trading is relatively constrained . This scarcity, combined with the strong buy signals from entities like CalSTRS and BlackRock, has helped drive the stock price closer to its 52-week high of $100.93 . The buyback program further reduces the share count, potentially increasing earnings per share over time and enhancing shareholder value.

What Is the Outlook for MetLife's Capital Return Strategy?

MetLife’s commitment to returning capital to shareholders is a central pillar of its current strategy. The $3 billion buyback authorization, coupled with a steady dividend yield of 2.5%, provides a dual mechanism for value creation . The company’s strong ROE of 23.39% and net margin of 4.57% indicate that it generates sufficient excess capital to support these initiatives without compromising its financial strength . Analysts view this balanced approach as a key driver for future stock appreciation, particularly in a rising interest rate environment where insurance companies can reinvest premiums at higher yields.

While the revenue miss in Q2 2026 presents a minor headwind, the strong EPS beat and robust capital return programs have largely overshadowed this concern. The combination of institutional buying, analyst upgrades, and management confidence suggests that MetLife is well-positioned to sustain its upward momentum. Investors are likely to remain focused on the company’s ability to maintain its high ROE and execute its buyback program effectively in the coming quarters.